Prognosis
Amgen Drug Shrank 37% of Lung Cancer Tumors in Study
- Sotorasib targets KRAS mutation, considered undruggable
- Amgen has filed with U.S. FDA, other global regulators
This article is for subscribers only.
An Amgen Inc. lung cancer drug shrank tumors in 37% of patients for whom chemotherapy and other drugs hadn’t worked, and prevented malignancies from progressing for a median of 6.8 months, the company said on Thursday.
The drug, sotorasib, targets an aggressive genetic mutation known as KRAS. About 30,000 lung cancer patients carry the KRAS G12C mutation the treatment targets. If approved, sotorasib will be the first direct inhibitor of the mutation, said Greg Friberg, vice president and therapeutic head, global development at Amgen.